{"url_path":"/sec/mmed/8-k/2026-06-29/item-404","section_key":"item-404","section_title":"Item 404 (a) of Regulation S-K, and there is no arrangement or understanding pursuant to which he was selected as a director","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/2062583/0001104659-26-078588-index.html","accession_number":"0001104659-26-078588","cik":"0002062583","ticker":"MMED","issuer_name":"MiniMed Group, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2062583/0001104659-26-078588-index.html","primary_entity_key":"0002062583","primary_entity_name":"MiniMed Group, Inc."},"word_count":297,"has_tables":true,"body_markdown":"Item 404(a) of Regulation S-K, and there is no arrangement or understanding pursuant to which he was selected as a director\nof the Board.\n\n \n\nMr. Endicott’s compensation for service as a director will be\nconsistent with the compensation paid to other non-employee directors of MiniMed as described in MiniMed’s Form 8-K filed\nwith the SEC on March 9, 2026.\n\n \n\nMs. Burman will serve as a class II director whose term expires at\nthe 2027 annual meeting of stockholders.  \n\n \n\nMs. Burman currently serves as Senior Vice President & President,\nNeurovascular at Medtronic plc (“Medtronic”). From May 2020 to May 2024, Ms. Burman served as Vice President & General\nManager, Enabling Technologies: Cranial & Spinal Technologies at Medtronic. Prior to these roles, Ms. Burman held various leadership\npositions at Medtronic over a tenure spanning more than 19 years, including Vice President & General Manager, Pelvic Health &\nGastric Therapies, Neurosciences Vice President of Strategic Planning & Communications, and Director of Marketing, US Pain Stimulation\n& Targeted Drug Delivery, as well as earlier marketing and market development roles. Ms. Burman holds a B.A. in Communication Studies,\nwith an emphasis in Public Relations from Virginia Tech.\n\nMs. Burman does not have a material interest in any transaction that\nis required to be disclosed under Item 404(a) of Regulation S-K, and there is no arrangement or understanding pursuant to which\nshe was selected as a director of the Board.\n\n \n\nFor so long as Medtronic is an affiliate of MiniMed, Ms. Burman, as\nan employee of Medtronic, will receive no compensation for her service on the Board. Thereafter, Ms. Burman’s compensation for service\nas a director will be consistent with the compensation paid to other non-employee directors of MiniMed as described in MiniMed’s\nForm 8-K filed with the SEC on March 9, 2026."}